Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen